Systemic Mastocytosis with Abdominal Pain: Management in Indolent or Smoldering Disease
Patients with indolent or smoldering systemic mastocytosis commonly experience significant gastrointestinal burden — including abdominal pain, cramping, diarrhea, heartburn, nausea, and vomiting — that requires specific therapeutic attention beyond general mast cell stabilisation.
This protocol targets patients with indolent or smoldering systemic mastocytosis presenting with abdominal pain, cramping, diarrhea, heartburn, nausea, or vomiting. Management priorities in this population focus on symptom control, anaphylaxis prevention, and addressing related complications such as osteoporosis.
Treatment Approach
The regimen for this scenario involves a corticosteroid-based strategy, with the specific agent, starting approach, and tapering framework tailored to individual response and tolerance.
Full dosing guidance, decision criteria, and the complete therapeutic algorithm are available in the structured protocol below.
References
- Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
- Prednisone 0.5–1 mg/kg/d starting dose; taper as feasible based on response/tolerance.
DOI: 10.1002/ajh.26962
View source ↗